Phase 2
Completed N=38
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Source: ClinicalTrials.gov NCT04880863 ↗Enrolled (actual)
38
Serious AEs
42.1%
Results posted
Mar 2025
Primary outcomePrimary: Objective Response Rate (ORR) — 15.6 percentage of responders
Summary
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5. Starting cycle 7, NAP at a higher dose will be administered on Day 1 only and docetaxel on Day 2, in 21 days treatment cycles. When NAP is administered as monotherapy and not earlier than cycle 7, NAP will be administered on Day 1 only and cycles will be of 28 days treatment cycle.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Objective Response Rate (ORR) |
15.6 | — |
| SECONDARY Disease Control Rate (DCR) |
71.9 | — |
| SECONDARY Duration of Response (DOR) |
12.2 | — |
| SECONDARY Progression-free Survival (PFS) |
8.8 | — |
| SECONDARY Overall Survival (OS) |
8.8 | — |
| SECONDARY Treatment-Emergent Adverse Events (TEAEs) |
37; 34; 28; 27; 18; 6 | — |
Eligibility Criteria
Main Inclusion Criteria:
- Subjects must be at least 18 years of age
- Subjects must have histologically and/or cytologically confirmed NSCLC
- Subjects must have incurable (advanced or metastatic) disease at the time of enrolment
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Subjects must provide signed informed consent prior to any study specific procedures that are not part of standard medical care.
- Subjects must have measurable neoplastic disease based on the iRECIST criteria
- Subjects must have received as least 1 and no more than 2 prior systemic regimens for the treatment of advanced/metastatic NSCLC. Patients are required to have progressed following treatment with both platinum-based chemotherapy and an anti-PD-(L)1 antibody administered either sequentially or concurrently. A prior PD-1/PD-L1 inhibitor is, however, not required if there was prior exposure to targeted therapies for a driver mutation positive tumors (e.g. EGFR or ALK inhibitors).
Main Exclusion Criteria:
- Subjects with active infection requiring treatment within 3 days of C1D1.
- Subjects with other active neoplastic disease requiring concurrent anti-neoplastic treatment
- Subjects with known, suspected or documented parenchymal brain metastases unless treated with surgery and/or radiation, with the subject neurologically stable and off pharmacologic doses of systemic glucocorticoids; subjects with leptomeningeal metastases are not eligible. Patients should have completed brain radiation for at least 14 days and be off steroids.
- Active or previously documented autoimmune or inflammatory disorders such as, but not limited to rheumatoid arthritis, systemic lupus erythematosus, uveitis, ulcerative colitis, Crohn's syndrome, Wegener's syndrome, multiple sclerosis, myasthenia gravis, scleroderma and sarcoidosis. The following are exceptions to this criterion:
- Vitiligo or psoriasis not requiring systemic treatment (within the last 2 years)
- Subjects with endocrinopathies (e.g. following Hashimoto syndrome) stable on hormone replacement or do not require any therapy.
- History of primary immunodeficiency
- Subjects with a history or prior allogeneic organ transplant
Data sourced from ClinicalTrials.gov (NCT04880863). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.